Zonghai Li, M.D., Ph.D., is the Executive Chairman, Chief Executive Officer, Chief Scientific Officer and Founder of CARsgen Therapeutics. He is also a professor in Shanghai Cancer Institute, Renji Hospital affiliated to Shanghai JiaoTong University School of Medicine. He is dedicated himself to develop curable treatment for the patients with cancer. One of his early career achievements is the identification of GE11, a peptide ligand of EGFR which has become the most widely used unnatural peptide in antitumor study now. He is the inventor of many new technologies such as Hpd3cell, a new phage display technology; FR806, a new safety switch for T cell therapy; Run-CAR technologies to increase the antitumor activities of CAR T cells. He has a leading role in the research on CAR T cell therapy against solid tumors by publishing the first paper of CAR T cell therapy against GPC3, Claudin18.2 and EGFR/EGFRvIII worldwide. He earned a M.D. and M.S. from Xiangya Medical School of Central South University and a Ph.D. from Shanghai Medical College of Fudan University.